

Supplementary Information S1 | p63 in human cancer

Tumour	p63 mutation	Expression		Specimen	p53 mutation	Refs
		RNA	IHC			
<b>p63</b>						
SCC-lung	Ala148Pro	ND	++	Human tumors	Not mutated	1
HNSCC	Ser145Leu	ND	++	Human cell lines	Not mutated	1
Cervical carcinoma	Gln165Leu	ND	++	Human cell lines	Not mutated	1
Bladder carcinoma	ND	ND	++	Human tumors (n=160)	ND	2
Metastatic breast adenocarcinoma	ND	ND	+	Matched human primary and metastatic tumor pairs (n=18)	ND	3
Lung adenocarcinoma	ND	ND	-	Human tumors (n=200)	ND	4
SCC	ND	ND	+	Human tumors (n=225)	ND	4
Actinic cheilitis	ND	ND	++	Human tumors (n=40)	ND	5
Lip SCC	ND	ND	++	Human tumors (n=65)	ND	5
Urothelial carcinoma	ND	ND	++	Human tumors (n=50)	ND	6
Prostate adenocarcinoma	ND	ND	-	Human tumors (n=50)	ND	6
Oesophageal SCC	ND	ND	++	Human tumors (n=65)	ND	7
Thymoma	ND	ND	++	Human tumors (n=583)	ND	8
B-cell lymphoma	ND	ND	++	Human tumors (n=583)	ND	8
Squamous and transitional carcinoma	ND	ND	-	Human tumors (n=583)	ND	8
Endometroid tumor	ND	ND	++	Human tumors (n=583)	ND	8
Dysplastic urothelium	ND	ND	+	Human tumors (n=30)	ND	9
Urothelial carcinoma of the bladder	ND	ND	-	Human tumors (n=30)	ND	9
Prostate cancer (neoplastic lesions)	ND	ND	+	Human tumors (n=90)	ND	10
Breast (invasive ductal carcinoma)	ND	ND	-	Human tumors (n=100)	ND	11
Transitional bladder carcinoma	ND	ND	++	Human tumors (n=158)	ND	12

Invasive bladder carcinoma	ND	ND	-	Human tumors (n=158)	ND	12
Lung SCC	ND	ND	++	Human tumors (n= 81)	ND	13
Lung adenocarcinoma	ND	ND	-	Human tumors (n= 237)	ND	13
ER <sup>+</sup> breast adenocarcinoma (low grade)	ND	+	++	Human tumors (n=2158)	ND	14
ER <sup>+</sup> breast adenocarcinoma (high grade)	ND	-	-	Human tumors (n=2158)	ND	14
Prostate adenocarcinoma	ND	ND	++ (cytoplasmic)	Human tumors (n=298)	ND	15
Small cell carcinoma	ND	ND	+	Human tumors (n=30)	ND	16
Urothelial carcinoma of the bladder (high grade)	ND	ND	+	Human tumors (n=30)	ND	16
Associated with B-cell leukemia	Yes in exon 4 Ala111Thr	ND	+	Human (n=1)	ND	17
<b>p63<math>\alpha</math></b> (TA and $\Delta$ N)						
Non-invasive bladder carcinoma	ND	ND	+	Human tumors (n=202)	Mutation not specified	18
Invasive bladder carcinoma	ND	ND	-	Human tumors (n=202)	Mutation not specified	18
<b><math>\Delta</math>Np63</b>						
Non-invasive bladder carcinoma	ND	ND	-	Human tumors (n=202)	Mutation not specified	18
Invasive bladder carcinoma	ND	ND	+	Human tumors (n=202)	Mutation not specified	18
Nasopharyngeal carcinoma	Not mutated	+	++	Human tumors (n=25)	Not mutated	19
Invasive bladder carcinoma	ND	ND	+	Human tumors (n=202)	Mutation not specified	20
Bladder carcinoma (low grade)	ND	ND	-	Human tumors (n=49)	ND	21
Bladder carcinoma (high grade)	ND	ND	++	Human tumors (n=49)	ND	21
Lung adenocarcinoma	ND	+	+	Human tumors (n=92)	ND	22
Lung adenocarcinoma	ND	ND	-	Human tumors (n=17)	ND	23

Lung SCC	ND	ND	+	Human tumors (n=17)	ND	23
HNSCC	ND	++	++	Human cell lines (n=2)	ND	24
HNSCC	ND	++	ND	Human tumors (n=36)	ND	25
HNSCC	ND	ND	++	Human tumors (n=24)	ND	26
Non-Hodgkin's lymphoma	ND	ND	++	Human tumors (n=11)	ND	26
NSCLC	ND	++	++	Human tumors (n=46)	ND	27
Bladder carcinoma	Not mutated	ND	-	Human tumors (n=47)	Mutated (34.8%) Mutation not specified.	28
<b>TAp63</b>						
Mammary adenocarcinoma (low grade)	ND	ND	+	Human tumors (n=43)	ND	29
Mammary adenocarcinoma (high grade)	ND	ND	-	Human tumors (n=43)	ND	29
HNSCC (low grade)	ND	+	+	Human tumors (n=46)	ND	29
HNSCC (metastatic)	ND	-	-	Human tumors (n=46)	ND	29
Lung adenocarcinoma (low grade)	ND	+	ND	Patient (n=92)	ND	29
Lung adenocarcinoma (high grade)	ND	-	ND	Patient (n=92)	ND	29
HNSCC	ND	ND	+	Human tumors (n=24)	ND	26
Colon carcinoma	ND	ND	+	Human tumors (n=6)	ND	26
NSCLC	ND	-	-	Human tumors (n=46)	ND	27
Bladder carcinoma	Not mutated	ND	-	Human tumors (n=47)	Mutated (34.8%) Mutation not specified.	28

ER, oestrogen receptor; HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry; ND, not determined; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.

- undetectable expression
- + expression detected
- ++ high expression detected

**References:**

1. Osada, M. et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. *Nat Med* **4**, 839-43 (1998).
2. Urist, M.J. et al. Loss of p63 expression is associated with tumor progression in bladder cancer. *Am J Pathol* **161**, 1199-206 (2002).
3. Shao, M.M. et al. A subset of breast cancer predisposes to brain metastasis. *Med Mol Morphol* **44**, 15-20.
4. Terry, J. et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. *Am J Surg Pathol* **34**, 1805-11.
5. Xavier, F.C., Takiya, C.M., Reis, S.R. & Ramalho, L.M. p63 Immunoexpression in lip carcinogenesis. *J Mol Histol* **40**, 131-7 (2009).
6. Din, N.U., Qureshi, A. & Mansoor, S. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. *Indian Journal of Pathology and Microbiology* **54**, 59-62 (2011).
7. Hara, T. et al. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. *Int J Mol Med* **14**, 169-73 (2004).
8. Di Como, C.J. et al. p63 expression profiles in human normal and tumor tissues. *Clin Cancer Res* **8**, 494-501 (2002).
9. Stepan, A., Margaritescu, C., Simionescu, C. & Ciurea, R. E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder. *Rom J Morphol Embryol* **50**, 461-5 (2009).
10. Hull, D. et al. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. *BJU Int* **104**, 915-8 (2009).
11. Ribeiro-Silva, A. et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. *Histopathology* **47**, 458-66 (2005).
12. Comperat, E. et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. *Virchows Arch* **448**, 319-24 (2006).
13. Bishop, J.A. et al. HPV Analysis in Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Squamous Cell Carcinoma. *Am J Surg Pathol* **36**, 142-8.
14. Hanker, L. et al. Clinical relevance of the putative stem cell marker p63 in breast cancer. *Breast Cancer Res Treat* **122**, 765-75.
15. Dhillon, P.K. et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. *Cancer Epidemiol Biomarkers Prev* **18**, 595-600 (2009).
16. Buza, N., Cohen, P.J., Pei, H. & Parkash, V. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder. *Int J Surg Pathol* **18**, 94-102.
17. Cabanillas, M. et al. A Novel Heterozygous Point Mutation in the p63 Gene in a Patient with Ectodermal Dysplasia Associated with B-Cell Leukemia. *Pediatr Dermatol* **28**, 707-10.
18. Karni-Schmidt, O. et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. *Am J Pathol* **178**, 1350-60.
19. Crook, T., Nicholls, J.M., Brooks, L., O'Nions, J. & Allday, M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? *Oncogene* **19**, 3439-44 (2000).
20. Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. & Cordon-Cardo, C. Molecular pathways of urothelial development and bladder tumorigenesis. *Urol Oncol* **28**, 401-8.
21. Comperat, E. et al. p63 gene expression study and early bladder carcinogenesis. *Urology* **70**, 459-62 (2007).
22. Narahashi, T. et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. *Histopathology* **49**, 349-57 (2006).

23. Uramoto, H., Yamada, S. & Hanagiri, T. Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. *Anticancer Res* **30**, 4717-20.
24. Rocco, J.W., Leong, C.O., Kuperwasser, N., DeYoung, M.P. & Ellisen, L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. *Cancer Cell* **9**, 45-56 (2006).
25. Sniezek, J.C., Matheny, K.E., Westfall, M.D. & Pietenpol, J.A. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. *Laryngoscope* **114**, 2063-72 (2004).
26. Nylander, K. et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. *J Pathol* **198**, 417-27 (2002).
27. Iacono, M.L. et al. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. *J Thorac Oncol* **6**, 473-81.
28. Park, B.J. et al. Frequent alteration of p63 expression in human primary bladder carcinomas. *Cancer Res* **60**, 3370-4 (2000).
29. Su, X. et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. *Nature* **467**, 986-90.